Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383731 | 0.85 | MEN1 (0.39) | MEN1KMT2APRCPLIPEEPHX2 | |
| SCHEMBL4388886 | 0.84 | SMN1; SMN2 (0.48) | MEN1KMT2AGAAPRCPEPHX2 | |
| SCHEMBL4376858 | 0.83 | SMN1; SMN2 (0.38) | MEN1KMT2AGAAPRCPLIPE | |
| SCHEMBL4380318 | 0.82 | MEN1 (0.39) | MEN1KMT2AGAALIPEEPHX2 | |
| SCHEMBL4379101 | 0.81 | MEN1 (0.44) | MEN1KMT2AGAALIPEEPHX2 | |
| SCHEMBL4386166 | 0.81 | PRCP (0.42) | MEN1KMT2AGAAPRCPEPHX2 | |
| SCHEMBL4393199 | 0.81 | LIPE (0.46) | MEN1KMT2ALIPEEPHX2SMN1; SMN2 | |
| SCHEMBL4390246 | 0.80 | MEN1 (0.41) | MEN1KMT2ALIPEEPHX2EPHX1 | |
| SCHEMBL4377024 | 0.80 | LMNA (0.38) | MEN1KMT2AGAAPRCPEPHX2 | |
| SCHEMBL4387768 | 0.80 | CYP2C19 (0.42) | MEN1KMT2APRCPEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | MEN1 3694/4885KMT2A 2079/4885GAA 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.